Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 06:30PM GMT
Release Date Price: $122.61
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

All right. Let's go ahead and get started. Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by [Malcolm Cuneo] and Priyanka Grover from the team. Our next presenting company is Sarepta. And presenting on behalf of the company, we have CEO, Doug Ingram. Doug?

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you, Anupam. Thanks, everyone, for joining us today, and thanks for those joining us online as well. We'll go 2 slides forward. I'll try my best to -- for those online, to remember try to reference slide numbers as I know that the slides don't automatically go forward. So for the last many years, we've been building, and we've been building frenetically.

We gathered together the pipeline and the people. We built a balance sheet. We gained multiple approvals. We've served the Duchenne community. We've been advancing our pipeline. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot